Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus TERRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus TERRAMYCIN.
ACHROMYCIN vs TERRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
250-500 mg orally every 6 hours or 1-2 g intravenously every 12 hours. Maximum oral dose: 2 g/day.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life: 8-10 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (creatinine clearance <10 mL/min).
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Renal (primarily glomerular filtration, 20-60% unchanged in urine), biliary/fecal (10-30% via bile into feces).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic